thyroid cancer Dec 7, 2021 Pan-Cancer Analysis Reveals Unique Features in Tumors From Younger People Oct 8, 2021 AffyImmune Raises $30M in Series A Funding to Advance Solid Tumor CAR T-Cell Therapy Oct 1, 2021 UK's NICE Recommends Selpercatinib for RET-Altered Thyroid Cancers Through Cancer Drugs Fund Apr 6, 2021 Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting Mar 11, 2021 Fore Biotherapeutics Enters Pharma Business With BRAF Inhibitor as Lead Product Premium Dec 22, 2020 Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients Dec 10, 2020 Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer Dec 2, 2020 Genentech, Blueprint Medicines' Gavreto Receives FDA Approval in RET-Altered Thyroid Cancer Premium Jul 14, 2020 Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors Jul 1, 2020 Blueprint Medicines Files NDA for Pralsetinib for RET-Driven Thyroid Cancers Jun 10, 2020 Bayer Continuing Vitrakvi Studies to Improve Understanding of Activity In Specific Tumor Types Premium Jun 9, 2020 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program Jun 5, 2020 Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type Jun 2, 2020 Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients Premium May 11, 2020 FDA Approves Lilly's Retevmo for RET-Driven Lung, Thyroid Cancers Apr 21, 2020 ArcherDx, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers Apr 1, 2020 Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications Dec 30, 2019 Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer Sep 9, 2019 Thermo Fisher Scientific, Eli Lilly to Develop CDx for RET Inhibitor Jul 18, 2019 Helomics Inks Separate Pacts With UPMC, Interpace Dx for AI-Driven Oncology Decision Making Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
